• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 3. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Halopyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Halopyrimidines

In-Depth Analysis of (S)-Tert-butyl 1-(5-fluoropyrimidin-2-yl)ethylcarbamate (CAS: 905587-30-6): A Versatile Building Block in Modern Pharmaceutical Chemistry

The compound (S)-Tert-butyl 1-(5-fluoropyrimidin-2-yl)ethylcarbamate (CAS: 905587-30-6) has emerged as a critical intermediate in the synthesis of bioactive molecules, particularly in the development of targeted therapies. With its unique fluoropyrimidine scaffold and chiral tert-butyl carbamate moiety, this compound offers unparalleled versatility in drug design. Researchers are increasingly focusing on its applications in kinase inhibitors and small-molecule therapeutics, aligning with the growing demand for precision medicine solutions.

One of the most searched questions in pharmaceutical forums revolves around "how to improve the yield of (S)-Tert-butyl 1-(5-fluoropyrimidin-2-yl)ethylcarbamate synthesis." Recent studies highlight optimized protocols using palladium-catalyzed cross-coupling or asymmetric hydrogenation, which achieve >90% enantiomeric purity. The 5-fluoropyrimidine group's metabolic stability makes this compound particularly valuable for proteolysis-targeting chimera (PROTAC) development—a hot topic in 2024 drug discovery trends.

From an analytical perspective, 905587-30-6 exhibits distinct NMR spectral characteristics (δ 8.7 ppm for pyrimidine-H, 1.4 ppm for tert-butyl), frequently discussed in structure elucidation communities. Its logP value of 2.1 suggests favorable membrane permeability, explaining its popularity in CNS drug development—another trending search term among medicinal chemists. The Boc-protected amine functionality allows selective deprotection, enabling modular structure-activity relationship (SAR) studies.

Environmental considerations are shaping synthesis approaches, with green chemistry enthusiasts searching for "solvent-free preparation of fluoropyrimidine derivatives." Innovative methods using mechanochemical activation or continuous flow chemistry demonstrate 40% reduction in organic waste compared to traditional routes. These sustainable practices align with ESG-compliant pharmaceutical manufacturing—a priority for regulatory bodies worldwide.

The compound's role in next-generation antiviral agents has gained attention post-pandemic. Computational studies reveal its molecular docking potential against conserved viral polymerase domains, particularly when incorporated into nucleoside mimetics. This application dominates recent PubMed citations and Google Scholar alerts related to 905587-30-6.

Quality control discussions emphasize HPLC method development for this compound, with researchers seeking "validated chiral separation of (S)-Tert-butyl carbamate derivatives." Advanced UHPLC-UV/MS methods now achieve baseline resolution (Rs >2.0) using polysaccharide-based chiral columns, addressing a common pain point in GMP-compliant production.

Emerging applications in radiopharmaceuticals have sparked interest, as the fluorine-18 analog shows promise for PET tracer development. This connects to trending searches about "fluorine-containing PET ligands" and "blood-brain barrier penetrating agents." The compound's boronic ester derivatives are also gaining traction in Suzuki-Miyaura coupling reactions for bioconjugation applications.

Patent landscape analysis reveals a 300% increase in filings involving 905587-30-6 since 2020, particularly for BTK inhibitors and EGFR tyrosine kinase modulators. This commercial interest correlates with search volume spikes for "pharmaceutical intermediates for oncology drugs"—underscoring the compound's relevance in cancer therapeutics development.

Stability studies indicate the tert-butyloxycarbonyl (Boc) group provides excellent protection under pH 2-8, making it ideal for oral drug formulations—a key consideration for formulation scientists searching "acid-labile protecting groups." Accelerated stability testing shows <95% purity retention after 6 months at 25°C when stored under nitrogen atmosphere.

The scientific community continues exploring structure-property relationships of this compound, with particular focus on its hydrogen bonding capacity (calculated PSA: 65 ?2) and crystal packing behavior. These properties influence polymorph selection during pharmaceutical crystallization processes—an area receiving growing attention in QbD (Quality by Design) initiatives.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)